Previous 10 | Next 10 |
REDWOOD CITY, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Kristine Ball, chief financial officer of Menlo Therape...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had a tumultuous week, dipping from 3,330.51 points on Monday (August 19) to 3,257.94 points at 12:22 p.m. EDT on Friday (August 23). On Monday, Nabriva (NASDAQ: NBRV ) notched its first approval from the US Food and Drug Administration (F...
The following slide deck was published by Menlo Therapeutics Inc. in conjunction with this Read more ...
Menlo Therapeutics (NASDAQ: MNLO ): Q2 GAAP EPS of -$0.69 beats by $0.15 . More news on: Menlo Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Results from Serlopitant Phase 2 Clinical Trial for the Treatment of Chronic Pruritus of Unknown Origin Anticipated in Q1 2020 Results from Serlopitant Phase 3 Clinical Trials for the Treatment of Pruritus with Prurigo Nodularis Anticipated in H1 2020 REDWOOD CITY, Calif., Aug....
REDWOOD CITY, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Menlo’s Chief Executive Officer, wi...
Introduction RegeneRx ( OTCQB:RGRX ) is a small cap ($21M) clinical-stage biopharma developing therapeutics for tissue protection, repair and regeneration. RegeneRx has a diverse clinical pipeline comprising RGN-259 , RGN-352 and RGN-137 . The pharmacological target for RGN-137 and...
Introduction Menlo Therapeutics ( MNLO ) is a small-cap ($103M) clinical-stage biopharmaceutical company developing innovative drug candidates therapeutically targeting neurokinin-1 receptor (NK1-R). Serlopitant (formerly VPD-73) is an oral once-daily selective NK1-R antagonist being clini...
NEW YORK , July 15, 2019 /PRNewswire/ -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the July 11 th life sciences conference are now available for on-demand viewing at VirtualInvestorConferences.com....
Life Science Company Live Investor Conference July 11th Canada NewsWire NEW YORK, July 9, 2019 Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com NEW YORK , July 9, 2019 /CNW/ - Virtual Investor Conference...
News, Short Squeeze, Breakout and More Instantly...
BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22 nd Annual Global Investment Confe...
BRIDGEWATER, N.J. , Sept. 8, 2020 /PRNewswire/ -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from "MNLO" to "...
Company will commence trading under new ticker “VYNE” on September 8, 2020 Company to ring Nasdaq Closing Bell on September 8 BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”...